Browsing Tag
Humacyte Inc.
1 post
Humacyte’s dialysis bet gains momentum, but $0.71 stock still reflects major execution risk
HUMA jumps 22% as peer-reviewed ATEV Phase 3 data strengthen Humacyte’s planned FDA filing for a potentially much larger dialysis market.